ABOUT US
Formed in 2006, CMDBioscience LLC specializes in peptide drug discovery and peptide research. As a privately held computational biotechnology company our main focus is on creating peptide drug discovery collaborations and the application of our computational peptide discovery platform CMDInventusSM to enable the discovery, design and optimization of novel therapeutic peptides. The core CMDBioscience technological advantage derives from our uniquely accurate, fast and robust methodology for estimating binding affinities and our de novo peptide ligand design algorithm. CMDBioscience is actively seeking growth opportunities through strategic partnerships.
Accelerating Peptide Discovery
Copyright 2012: CMD Bioscience. Computational Biotechnology. All rights reserved.
5 Science Park New Haven, CT 06511 203-298-4251 | info@cmdbioscience.com
CMD Bioscience Peptide Research
Peptides have a wide range of applications in the technological realm. They can be applied in all sorts of situations, from pharmaceutical agents to diagnostic agents, to tool agents that can be used to unlock the mysteries of biology.
CMDBioscienceSM has been a part of several mutually beneficial collaborations with other technology companies, striving to develop new product opportunities. Our emphasis is in furthering the goals of the biotechnology, pharmaceutical and life science industries.
For more information about our collaborations with various academic institutions, biomedical companies, pharmaceutical companies and technology companies, visit our Partnerships page. If you would like to share any comments or pose questions about our computational biotechnology products or partnerships with other organizations, feel free to contact us.
Executive Team
Joseph Audie, PhD
Chief Executive Officer
A founding member of CMDBioscience, Dr Joseph Audie is responsible for developing the proprietary computational methods that serve as the core technology used by the company today. Dr Audie received a BS in Bioengineering from Hofstra University, an MS in Biomedical Engineering from the University of Connecticut, Storrs, and a PhD in Biophysics from the State University of New York, Stony Brook.
Charles Boyd, PhD
Chief Investigational Scientist
Dr Boyd received his Bachelor of Arts degree in Biochemistry and Molecular Biology from the University of California, Berkley, and his PhD in Biochemistry and Molecular Biology from the University of California, Los Angeles. He has served as a research fellow in Hepatology and Gastroenterology at Yale University School of Medicine. Dr Boyd brings with him 15 years of academic and pharmaceutical research experience in fields such as in-vivo protein dynamics, membrane trafficking, and immunohistology.
Thomas E Gerson
Chief Financial Officer
With over 30 years in finance and 20 years with Biotech and Pharmaceutical companies, Tom is a seasoned executive in the field of Biotechnology. Most recently acting as Chief Financial Officer and VP, Operations for HistoRx, a privately-held medical device and diagnostics company focused on measurement and analysis of biomarkers, Tom was responsible for raising over $10 million in private capital in 2007 and 2008. In addition, Tom implemented business strategy to increase revenue from key pharmaceutical partners leading to $5MM in 2008, negotiating annual $2MM commitment from Lilly with upfront quarterly payments.
Scientific Advisory Board
David Beveridge, PhD
David Beveridge, Ph.D. is University Professor of the Natural Sciences and Mathematics, and Professor of Chemistry and Director NIGMS Molecular Biophysics Training Program at Wesleyan University. His current research involves theoretical studies and computational modeling studies on the structure, motions, solvation, and ligand binding properties of DNA, RNA and proteins using molecular dynamics simulation-based techniques.
Benjamin Wolozin, MD, PhD
Benjamin Wolozin, M.D., Ph.D. is a professor of Pharmacology and Neurology at the Boston University School of Medicine. Dr. Wolozin’s research investigates the pathophysiology of neurodegenerative diseases. His research on Parkinson’s Disease focuses on understanding the interaction between genetic factors implicated in the disease and environmental factors utilizing cell culture, mammalian brain slice culture and transgenic lines of C. elegans. Results are then investigated further in transgenic/knockout mice and in human brain samples or cell lines from patients. His projects also focus on identifying pharmacological strategies for Parkinson’s disease. The research on Alzheimer’s disease focuses on the interaction between the proteins that produce beta-amyloid and the genes that regulate cholesterol metabolism. Finally, Dr. Wolozin has an active epidemiological research program that examines the effects of FDA-approved medications on the incidence and progression of both Alzheimer’s and Parkinson’s disease.
Erick Suchanek, PhD
Dr Suchanek received his PhD in biochemistry and biophysics from John's Hopkins Medical School in Baltimore, MD. Dr Suchanek worked for Proctor and Gamble for over 20 years beginning as a company scientist assuming increasing roles of responsibility. He retired in 2009 as Section Head for the Global Modeling Community. Dr Suchanek has extensive industrial expertise in small molecule drug design methods and QSAR and is experienced in methods for conformer analysis and optimization, de novo drug design, pharmacophore modeling, molecular mechanics, quantum mechanics, and virtual screening.
Victor J. Hruby, PhD
Dr Hruby received his PhD from Cornell University and is Regents Professor Emeritus of Chemistry, Professor Emeritus of Biochemistry and Molecular Biophysics, Professor Emeritus, Arizona Research Laboratories, Professor Emeritus of Neuroscience, Professor Emeritus of Medical Pharmacology at the University of Arizona. Dr. Hruby's research focuses on the design, synthesis, and analysis of biologically active peptides and peptide mimetics, with a special emphasis on the hormones and neurotransmitters affecting human behavior. Dr. Hruby is a world-renowned expert in the fields of rational antihormone development, design and asymmetric synthesis of conformationally constrained amino acids, peptides and peptide mimetics, and in the use of NMR and other physical methods to examine peptide and peptidomimetic conformations.
Bernhardt L. Trout, PhD
Professor Trout received his SB and SM degrees from MIT and his PhD from the University of California at Berkeley. In addition, he performed postdoctoral research at the Max-Planck Institute. Prof. Trout’s research focuses on molecular engineering for the stabilization of biotherapeutics, crystallization, and the development of pharmaceutical separation processes. He is currently Director of the Novartis-MIT Center for Continuous Manufacturing and the Co-Chair of the Singapore-MIT Alliance Program on Chemical and Pharmaceutical Engineering. He has published over 80 papers and currently has 4 patent applications submitted.
